[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Biotech Beast posts on X about alt, $alt, $repl, $akro the most. They currently have XXXXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.
Social topic influence alt, $alt, $repl, $akro, $etnb, $xbi
Top assets mentioned AltLayer (ALT) Akropolis (AKRO) Bitcoin Incognito (XBI)
Top posts by engagements in the last XX hours
"$ALT has recovered slightly the past month since data from the IMPACT trial of pemvidutide in MASH produce mixed results at XX weeks. The fibrosis improvement isn't on par with $ETNB and $AKRO although pemvidutide has other advantages" @Biotech_Beast on X 2025-07-24 15:28:10 UTC 1718 followers, XXX engagements
"Some pretty brutal language in the $REPL CRL press release today. "The FDA has indicated that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness."" @Biotech_Beast on X 2025-07-22 11:21:54 UTC 1718 followers, 1009 engagements
"If $REPL gets a CRL tomorrow the whole sector could tank as it would confirm a tougher FDA or at least CBER And if it is approved could clear up a whole lot of FDA uncertainty the sector is facing. Hope it is the latter. $XBI" @Biotech_Beast on X 2025-07-21 16:30:38 UTC 1718 followers, 12.4K engagements
"There is still a 48-week update coming for $ALT and business development is always a possibility. Still the company missed one of its best chances to display the value of pemvidutide in a more resounding fashion" @Biotech_Beast on X 2025-07-24 15:29:44 UTC 1718 followers, XXX engagements